Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/220512
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartínez Limón, Adrián-
dc.contributor.authorJoaquin i Caudet, Manel-
dc.contributor.authorCaballero de la Torre, María-
dc.contributor.authorPosas, Francesc-
dc.contributor.authorNadal Clanchet, Eulàlia de-
dc.date.accessioned2025-04-22T09:25:21Z-
dc.date.available2025-04-22T09:25:21Z-
dc.date.issued2020-03-01-
dc.identifier.issn1422-0067-
dc.identifier.urihttps://hdl.handle.net/2445/220512-
dc.description.abstractThe p38 MAPK pathway is well known for its role in transducing stress signals from the environment. Many key players and regulatory mechanisms of this signaling cascade have been described to some extent. Nevertheless, p38 participates in a broad range of cellular activities, for many of which detailed molecular pictures are still lacking. Originally described as a tumor-suppressor kinase for its inhibitory role in RAS-dependent transformation, p38 can also function as a tumor promoter, as demonstrated by extensive experimental data. This finding has prompted the development of specific inhibitors that have been used in clinical trials to treat several human malignancies, although without much success to date. However, elucidating critical aspects of p38 biology, such as isoform-specific functions or its apparent dual nature during tumorigenesis, might open up new possibilities for therapy with unexpected potential. In this review, we provide an extensive description of the main biological functions of p38 and focus on recent studies that have addressed its role in cancer. Furthermore, we provide an updated overview of therapeutic strategies targeting p38 in cancer and promising alternatives currently being explored.-
dc.format.extent18 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms21061913-
dc.relation.ispartofInternational Journal Of Molecular Sciences, 2020, vol. 21, num. 6-
dc.relation.urihttps://doi.org/10.3390/ijms21061913-
dc.rightscc-by (c) Martínez Limón, Adrián et al., 2020-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut de Recerca Biomèdica (IRB Barcelona))-
dc.subject.classificationTerapèutica-
dc.subject.classificationCàncer-
dc.subject.classificationFosforilació-
dc.subject.classificationProteïnes supressores de tumors-
dc.subject.otherTherapeutics-
dc.subject.otherCancer-
dc.subject.otherPhosphorylation-
dc.subject.otherTumor suppressor protein-
dc.titleThe p38 pathway: From biology to cancer therapy-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2025-04-16T11:37:10Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.idimarina6239889-
dc.identifier.pmid32168915-
Appears in Collections:Articles publicats en revistes (Institut de Recerca Biomèdica (IRB Barcelona))

Files in This Item:
File Description SizeFormat 
IntJMolSci_Martínez_2020.pdf1.68 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons